Bristol Myers Squibb (BMY) is committing about US$2.3b to a new modular, multi modal manufacturing campus in Houston, Texas, aimed at supporting multiple medicine types and nearly 500 skilled jobs.

Bristol Myers Squibb’s share price has eased over the past week but still sits at US$63.61 after a strong run, with a 30 day share price return of 10.47% and a 1 year total shareholder return of 43.21%. This suggests momentum has been building alongside recent earnings, AI research partnerships and the new Houston manufacturing commitment.

If this mix of pharma expansion and AI partnerships interests you, it may be worth seeing what else is moving in healthcare focused AI by checking out 43 healthcare AI stocks

Bristol Myers Squibb now couples a broad drug portfolio with fresh capital committed to future production. The stronger question for investors is whether the recent share price run already reflects that strength or still leaves room in the valuation.

Most Popular Narrative: 1% Overvalued

The current Simply Wall St narrative pegs Bristol Myers Squibb’s fair value at $62.96, just below the last close of $63.61. This frames a very tight valuation gap based on detailed revenue and margin forecasts.

Robust late-stage pipeline and ongoing life-cycle management for major brands, plus strategic partnerships (BioNTech, Philochem, Bain), expand the breadth of future regulatory approvals and label expansions. This opens additional indications and helps to offset upcoming patent expiries, which underpins top-line and earnings growth.

Want to see why this narrative still arrives at a premium multiple despite forecast revenue declines and slimmer margins? The answer sits in a specific mix of late stage launches, profitability shifts and the price placed on those earnings in 2029.

Result: Fair Value of $62.96 (OVERVALUED)

However, Bristol Myers Squibb still faces key risks around upcoming patent expiries and pricing pressure, which could challenge margins and weaken this fair value narrative.

Another View on Bristol Myers Squibb’s Valuation

The narrative around Bristol Myers Squibb highlights a tight 1% premium to fair value, yet the current P/E of 14x tells a different story. It sits well below both the US Pharmaceuticals industry at 17.1x and peers at 57.1x, and under the 18.2x fair ratio Simply Wall St estimates the market could move toward. That gap suggests investors are still pricing in meaningful risk. The key question is whether you think the earnings and patent overhang justify that discount or if sentiment has swung too far.

Next Steps

If the mixed signals around Bristol Myers Squibb leave you on the fence, now is a good time to review the full picture and decide where you stand. To weigh the concerns against the potential upside, start by checking the 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Bristol Myers Squibb?

If Bristol Myers Squibb has sharpened your focus on quality, do not stop here. Broaden your watchlist with a few targeted ideas that could complement your portfolio.

• Identify potential mispriced opportunities by reviewing companies highlighted in the 49 high quality undervalued stocks.
• Explore income-focused investments by checking out the 8 dividend fortresses that may offer cash returns.
• Manage portfolio risk by focusing on the 85 resilient stocks with low risk scores that score well on resilience and financial stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.